CLINICAL TRIALS

 

DELIVERING HOPE TO PATIENTS.

STAY INFORMED

Due to a high volume of inquiries, we are asking patients to follow us on twitter for new trial and enrollment announcements. The moment we know, we will let you know!

Hope Biosciences' HB-AdMSCs are adipose-derived mesenchymal stem cells that have been processed through our proprietary cell culture platform. Learn more about our product here. We are using our cells to test various indications in cancer, autoimmune diseases and neurological conditions. 

 

For more information, follow the links below to the study listings on clinicaltrials.gov. Please visit our FAQ page for the answers to the most commonly asked questions. Have more questions? Please contact us!

 

Rheumatoid Arthritis


ClinicalTrials.gov Identifier: NCT03691909 Status: Enrollment Complete. Follow up in progress. Official Title: A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis




Parkinson's Disease


ClinicalTrials.gov Identifier: NCT04064983 Status: Enrollment Complete. Treatment in progress. Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's Disease




Spinal Cord Injury


ClinicalTrials.gov Identifier: NCT04064957 Status: Enrollment Complete. Treatment in progress. Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Chronic Spinal Cord Injury ClinicalTrials.gov Identifier: NCT03925649 Status: Enrollment Complete. Treatment complete. Follow up in progress. Collaborator: The University of Texas Health Science Center, Houston Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI




Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy


ClinicalTrials.gov Identifier: NCT04063215 Status: Enrolling Contact: Contact: Steven Kosmach, MSN 713-500-7329 Steven.Kosmach@uth.tmc.edu Contact: Joiya Arrington, MSN (713) 500-7395 Joiya.Arrington@uth.tmc.edu Collaborator: The University of Texas Health Science Center, Houston Official Title: A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy




Cerebral Palsy (Pediatric)


ClinicalTrials.gov Identifier: NCT04029896 Status: Enrollment Complete. Treatment in progress. Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy.




Alzheimer's Disease


ClinicalTrials.gov Identifier: NCT04228666 Status: ON HOLD UNTIL FURTHER NOTICE Due to the recent events of COVID-19, we have decided to delay this protocol until it is safe to resume. Official Title: A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease.




COVID-19 (Allogeneic Pre-treatment)


ClinicalTrials.gov Identifier: NCT04348435 Status: Enrollment in Progress Official Title: A Phase 2, Randomized, Placebo-Controlled, Clinical Trial to Assess Efficacy of Allogeneic HB-adMSCs to Provide Immune Support Against Coronavirus Disease. This trial is open to:

  • Men, and women 18 years of age or older
  • Participant works in a capacity that is characterized as high-risk or very high-risk
  • High-Risk Exposure jobs are those with high potential for exposure to known or suspected sources of COVID-19.
    • First responders, health care delivery and support staff (e.g., law enforcement, fire fighters, paramedics, doctors, nurses, and other hospital staff who must enter patients' rooms) exposed to individuals potentially having COVID-19.
    • Mortuary workers involved in preparing (e.g., for burial or cremation) the bodies of people who are known to have, or suspected of having, COVID-19 at the time of their death
  • Very High-Risk Exposure jobs are those with high potential for exposure to known or suspected sources of COVID-19 during specific medical, postmortem or laboratory procedures.
    • Health care workers (e.g., doctors, nurses, dentists, paramedics, emergency medical technicians) performing aerosol-generating procedures (e.g., intubation, cough induction procedures, bronchoscopies, some dental procedures and exams or invasive specimen collection) on known or suspected COVID-19 patients
    • Health care or laboratory personnel collecting or handling specimens from known or suspected COVID-19 patients (e.g., manipulating cultures from known or suspected COVID-19 patients)
    • Morgue workers performing autopsies, which generally involve aerosol-generating procedures, on the bodies of people who are known to have, or suspected of having, COVID-19 at the time of their death
If you meet any of these criteria and would like to paricipate in this trial, please apply here.




COVID-19 (Autologous Pre-treatment)


Clinicaltrials.gov Identifier : NCT04349631 Enrollment: Complete Status: Treatments in progress. Visit hopebio.org for updated progress. Official Title: A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19




COVID-19 (Allogeneic Treatment)


Clinicaltrials.gov Identifier : TBD Enrollment: On Hold. Site: River Oaks Hopsital & United Memorial Medical Center Official Title: A Phase II, Randomized, Placebo-Controlled, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19




Osteoarthritis


ClinicalTrials.gov Identifier: Coming Soon Status: Enrollment Complete. Treatment to start soon. Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Hip Osteoarthritis




Amyotrophic Lateral Sclerosis (ALS)


ClinicalTrials.gov Identifier: Coming Soon Status: Enrollment Complete. Treatment in progress. Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis





FOR NEWS RELEASES & MORE

  • Facebook - Grey Circle
  • Twitter - Grey Circle
  • Instagram - Grey Circle
  • LinkedIn - Grey Circle
  • YouTube - Grey Circle

Keep me up to date with news and exciting developments by email. I can unsubscribe at any time by contacting Hope Bio.

© 2019 Hope Biosciences.  All rights reserved.